Larazotide

Clinical Trials

Gut Health

A tight junction regulator peptide that reduces intestinal permeability (leaky gut) and shows promise for celiac disease treatment.

Administration

Oral capsule

Dosage Range

0.5-1 mg three times daily

Mechanism of Action

Larazotide acts as a zonulin antagonist, preventing the opening of tight junctions in the intestinal epithelium. This reduces intestinal permeability and prevents translocation of antigens across the gut barrier.

Clinical Benefits

Reduces intestinal permeability

Protects gut barrier function

Reduces celiac disease symptoms

Decreases systemic inflammation

Supports autoimmune condition management

Clinical Evidence

Phase III clinical trials for celiac disease (LARA-CD) demonstrated significant reduction in symptoms and intestinal permeability. Granted FDA Fast Track designation.

Side Effects

Mild GI discomfort

Headache

Nausea (uncommon)

Contraindications

Severe intestinal obstruction

Pregnancy

Known hypersensitivity

Related Peptides in Gut Health

KPV

A tripeptide derived from alpha-MSH with potent anti-inflammatory properties, particularly effective for gut inflammation and IBD.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.